Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974Jun Liu, Jennifer L. Harris, Shifeng Pan et al.|Proceedings of the National Academy of Sciences|2013Cited by 833
Targeting cardiac fibrosis with engineered T cellsHaig Aghajanian, Jonathan A. Epstein, Tōru Kimura et al.|Nature|2019Cited by 799
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE studyHagop M. Kantarjian, Anjali S. Advani, Daniel J. DeAngelo et al.|Cancer|2019Cited by 327
Epicardial YAP/TAZ orchestrate an immunosuppressive response following myocardial infarctionVimal Ramjee, Jonathan A. Epstein, Deqiang Li et al.|Journal of Clinical Investigation|2017Cited by 176
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 BlockadeAleix Prat, Mothaffar F. Rimawi, Tomás Pascual et al.|JNCI Journal of the National Cancer Institute|2019Cited by 168